Jeffrey Bertolini, the Chief Operating Officer of Carlsmed, Inc., recently filed a report detailing his stock transactions with the Securities and Exchange Commission. This filing is significant as it showcases the ongoing commitment of executives to their companies and their personal investments in the business.

Carlsmed, Inc. is a company in the surgical and medical instruments industry, specifically classified under the SIC code 3841. The firm is incorporated in Delaware and operates out of Carlsbad, California. Bertolini's recent filing is part of a series of disclosures that highlight his active role in managing his stock holdings.

The SEC filing, accession number 0001193125-26-447468, reveals that on November 3, 2026, Bertolini acquired 747 shares of common stock at a price of $5.915 per share. Additionally, he sold an equal number of shares at a higher price of $15.150 per share. Following these transactions, Bertolini retains ownership of 22,489 shares.

Furthermore, Bertolini exercised stock options to acquire another 747 shares of common stock at a conversion price of $5.915. This exercise is part of a stock option plan that vests over time, indicating a long-term commitment to the company.

These transactions may affect various stakeholders, including shareholders and potential investors, as they reflect the confidence of the company's leadership in its future performance. The surgical and medical instruments industry, where Carlsmed operates, is characterized by rapid innovation and competition, and such executive actions can signal to the market the health and direction of the company.

Looking ahead, it remains unclear what additional filings or corporate actions may follow these transactions. For now, the filing does not specify any upcoming events or changes related to Bertolini's role or the company's strategy.